Oxford
BioMedica Plc Appoints Nick L Woolf Senior Vice President
of Corporate Strategy
Oxford
BioMedica Plc (LSE: OXB) announced today that it has strengthened
its senior management with the appointment of Nick L Woolf
as Senior Vice President of Corporate Strategy.
With more
than eight years experience as a biotechnology and pharmaceutical
analyst, Nick has been involved in all aspects of company
financing, ranging from IPOs to major corporate deals. Most
recently he served as Director and Head of European Biotechnology
Research at ABN AMRO, where he was responsible for developing
its industry coverage. Prior to that, Nick was Vice President
and Senior Analyst at Robertson Stephens International where
he established its European biotechnology research product,
and was previously at both Nomura and SBC Warburg. Nick holds
a MA from Oxford University in Chemistry.
Alan Kingsman,
Chief Executive of Oxford BioMedica, said:
“I
am delighted to welcome Nick Woolf to the management team.
Nick will be of great benefit to the Company as we continue
to develop our business. He brings with him a wealth of industry
knowledge and capital markets experience, which I believe
will both strengthen and complement the management team already
in place.”
-Ends- |
Return to the News
| Notes
| 1. |
Oxford
BioMedica plc |
| |
Established
in 1995 as a spin out from Oxford University, Oxford
BioMedica is an international biotechnology company
with a diverse portfolio of products and technology,
specialising in gene-based products and technology in
the areas of cancer, neurological disease, cardiovascular
disease and blood disorders. This is underpinned by
over 70 patent families, about quarter of which are
issued. Oxford BioMedica plc was floated on the Alternative
Investment Market of the London Stock Exchange in December
1996, and was promoted to the United Kingdom Listing
Authority Official List in April 2001 following a successful
£35.5 million fund-raising.
Oxford
BioMedica is headquartered in Oxford, UK and has a wholly-owned
subsidiary in San Diego, USA.
Currently
Oxford BioMedica has corporate collaborations with Amersham,
Arius, Aventis, IDM, Valentis, Virbac and Wyeth. BioMedica
has two products in Phase I/II clinical trials: MetXia®
for late-stage breast cancer, and TroVax® for late-stage
colorectal cancer.
|
| 2. |
World Wide Web |
| |
Further
information is available on the World Wide Web at www.oxfordbiomedica.co.uk
and at www.ariusresearch.com. |
| For
further information please contact: |
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive |
Tel: +44 (0)1865 783 000 |
| City/Financial
Enquiries
Mike
Wort/James Chandler
Beattie Financial Communication |
Tel: +44 (0)20 7398 3300
|
| Scientific/Trade
Enquiries
Sue
Charles, Katja
Stout, Charles Consultants |
Tel:
+44 (0)20 7321 3870 |
|
|
|
Top
of page
Website by College Hill - Life Sciences |
| |
|
|
